Preclinical evaluation of CAR-T cell immunotherapy with a fully human EpCAM-specific scFv against pancreatic cancer
Ying-Ying Fan, Ya-Ling Liu, Xiao-Fan Liu, Si-Qi Jiang, Hui Yang, Hao-Ran Zhang, Ping Wei, Qian-Rong Huang · 2025
Read Preclinical evaluation of CAR-T cell immunotherapy with a fully human EpCAM-specific scFv against pancreatic cancer by Ying-Ying Fan, Ya-Ling Liu, Xiao-Fan Liu, Si-Qi Jiang, Hui Yang, Hao-Ran Zhang, Ping Wei, Qian-Rong Huang (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12717346.txt.
Description
Ying-Ying Fan and seven co-authors test an engineered immune cell therapy against pancreatic cancer in the lab, in a 2025 study. Pancreatic cancer is aggressive and short on good treatments. CAR-T therapy rewires a patient's own immune cells to hunt tumors.
The target here is EpCAM, a marker common on epithelial tumors. The hunting head of the cell was built fully from human parts. The cells killed EpCAM positive cancer cells in dishes, in 3D tumor balls, and in patient derived organoids. In two mouse models they shrank tumors without clear side effects. The results support moving toward human trials.
Catalog record
| CREATOR | Ying-Ying Fan, Ya-Ling Liu, Xiao-Fan Liu, Si-Qi Jiang, Hui Yang, Hao-Ran Zhang, Ping Wei, Qian-Rong Huang |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 56 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |